Jefferies Financial Group Analysts Give OrganiGram (CVE:OGI) a C$10.00 Price Target

OrganiGram (CVE:OGI) has been assigned a C$10.00 target price by analysts at Jefferies Financial Group in a report issued on Monday, February 25th. The firm presently has a “buy” rating on the stock. Jefferies Financial Group’s price target points to a potential upside of 8.46% from the company’s previous close.

Other research analysts have also recently issued research reports about the stock. Cormark raised their price target on shares of OrganiGram from C$5.50 to C$8.50 in a report on Tuesday, January 29th. Pi Financial raised their price target on shares of OrganiGram from C$8.00 to C$10.00 in a report on Tuesday, January 29th. Finally, Canaccord Genuity raised their price target on shares of OrganiGram from C$6.00 to C$7.50 and gave the stock an “average” rating in a report on Wednesday, December 19th.

Shares of OGI traded down C$0.17 during mid-day trading on Monday, hitting C$9.22. The company’s stock had a trading volume of 1,657,300 shares, compared to its average volume of 1,750,015. OrganiGram has a 52-week low of C$3.26 and a 52-week high of C$9.91. The company has a debt-to-equity ratio of 42.38, a quick ratio of 7.00 and a current ratio of 14.53. The stock has a market capitalization of $1.20 billion and a PE ratio of 24.85.

OrganiGram (CVE:OGI) last posted its earnings results on Monday, January 28th. The company reported C($0.02) EPS for the quarter. The company had revenue of C$12.44 million for the quarter, compared to the consensus estimate of C$13.87 million. Equities research analysts forecast that OrganiGram will post 0.370000006548673 EPS for the current year.

OrganiGram Company Profile

OrganiGram Holdings Inc, through its subsidiaries, produces and sells dried cannabis and cannabis oil in Canada. It also offers wholesale shipping of cannabis plant cuttings, dried flowers, blends, pre-rolls, and cannabis oils to retailers and wholesalers. The company also exports its products. It sells its products online, as well as through phone orders.

See Also: Balanced Fund

Receive News & Ratings for OrganiGram Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OrganiGram and related companies with MarketBeat.com's FREE daily email newsletter.